Total trials
96
Active
19
Phase 3
6
Total enrollment
33,741
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| TSR-022 and TSR-042 | — | — | — | — | — | 1 | |
| Ipilimumab and Nivolumab | — | — | — | — | — | 1 | |
| Nicotine Polacrilex Gum | — | — | — | — | — | 1 |
Next readouts
- 2026-03-06
- 2027-08-01
- 2027-11-01
Top conditions
- Type 2 Diabetes7
- Obesity6
- Hypertension6
- Breast Cancer4
- Overweight and Obesity4
- Physical Activity4
- HIV3
- Dyslipidemias3
Frequently asked questions about University of Hawaii
- How many clinical trials does University of Hawaii have on ClinicalTrials.gov?
- University of Hawaii is listed as the lead sponsor on 96 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Hawaii's trials are in Phase 3?
- 6 of University of Hawaii's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Hawaii focus on?
- University of Hawaii's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Obesity, Hypertension, Breast Cancer, Overweight and Obesity.
- When are University of Hawaii's next clinical trial readouts?
- University of Hawaii has 3 upcoming primary-completion readouts tracked here; the soonest is “TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer”, expected around 2026-03-06.